Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis with ocular involvement.~Exclusion Criteria:~* Patients receiving mono-amino-oxidase inhibitors.~* Patients with history of hypertension, cardiac, or cerebrovascular disease.~* Women with confirmed pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients (Type: EXPERIMENTAL): Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).